Jack Higgins, Chief Scientific Officer, Immunome (IMNM 2.72%)reported the sale of 9,438 shares of its widespread inventory in an open market transaction on April 2, 2026, as disclosed in an SEC Type 4 submitting.
Transaction abstract
Transaction quantity based mostly on SEC Type 4 reported value ($21.64). Put up-trade worth based mostly on market closing value on April 2, 2026 ($21.84). Gifted Shares: The 6,291 shares gifted on March 30, 2026 are excluded from all share counts, transaction quantities, and post-trade balances above.
Foremost query
How did this deal have an effect on Higgins’ total possession of Immunome?
Because of this sale, Higgins’ direct holdings decreased by 30.02% from 31,438 shares to 22,000 shares. Was the complete disposal carried out immediately or had been oblique holdings additionally affected?
The sale of the complete 9,438 shares was effected from direct holdings. Oblique shares attributable to his youngsters’s custodial accounts had been unaffected and remained at 3,000 shares. What’s the rationale and background behind the timing and technique of this sale?
This sale was executed based mostly on a prearranged Rule 10b5-1 buying and selling plan, supporting the view that this was routine liquidity administration quite than discretionary market timing. How does this transaction relate to Higgins’ historic buying and selling exercise?
Accessible EDGAR submitting historical past reveals 1 prior open market sale. 3,524 shares had been offered on August 15, 2024. At 9,438 shares, the deal is roughly 2.7 occasions the earlier sale.
Firm Profile
*Worth developments for one 12 months are calculated utilizing April 2, 2026 as the bottom date.
Firm snapshot
Immunome develops antibody therapeutics focusing on the oncology and infectious illness markets, with lead packages together with IMM-ONC-01 for most cancers and IMM-BCP-01 for SARS-CoV-2. The Firm operates a research-driven enterprise mannequin centered on the invention and development of proprietary antibody-based therapeutics. Immunome targets pharmaceutical corporations, healthcare suppliers, and sufferers within the oncology and infectious illness markets.
Immunome is a clinical-stage biotechnology firm centered on the invention and growth of antibody therapeutics for most cancers and infectious ailments. The corporate’s technique leverages its proprietary platform to handle unmet medical wants by novel immune-based therapies. Its aggressive benefit lies within the development of differentiated antibody packages with the potential to realize first-in-class or best-in-class profiles.
What this deal means for traders
The timing and value of this sale had been mounted a number of months prematurely of its execution. Higgins arrange a 10b5-1 buying and selling plan in December 2025 particularly for monetary diversification. This doesn’t imply that the CSO screens the inventory and decides to promote it. There are additionally no necessary possession necessities to drive decision-making. He has continued to speculate closely for the reason that sale, with a direct place price roughly $480,000 as of April 2’s closing value. Higgins brings related depth to this function. He co-invented the Engineered Toxin Physique platform for 11 years at Molecular Templates and accomplished a fellowship in tumor immunology on the Nationwide Most cancers Institute. This corresponds on to Immunome’s ADC-heavy pipeline. The actual story in Immunome proper now could be balegacestat. The Part 3 RINGSIDE trial will attain its major endpoint in December 2025, with NDA submitting deliberate for Q2 2026. This, together with early information on IM-1021 and three IND filings anticipated in 2026, is a noteworthy catalyst. The pre-planned government sale says little extra about Immunome’s prospects than these milestones.
Seena Hassouna has no place in any shares talked about. The Motley Idiot has no place in any shares talked about. The Motley Idiot has a disclosure coverage.
